Average Insider

Where insiders trade, we follow

$INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Healthcare
Sector
Biotechnology
Industry
William Meury
CEO
2617
Employees
$119.09
Current Price
$20.14B
Market Cap
52W Low$89.25
Current$119.0968.8% above low, 31.2% below high
52W High$132.60

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells15$1,292,031.9310,694
2 weeksBuys00--All Sells
Sells210$29,727,780.35250,887
1 monthBuys00--All Sells
Sells311$29,800,345.95251,497
2 monthsBuys00--All Sells
Sells412$30,098,125.77254,139
3 monthsBuys00--All Sells
Sells414$32,895,754.92277,357
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 13, 2026
Heeson Lee
EVP, Head of Incyte Intl
Sale2,449$121.13$296,652.27View Details
Nov 13, 2026
Heeson Lee
EVP, Head of Incyte Intl
Sale874$121.16$105,896.90View Details
Nov 13, 2026
Heeson Lee
EVP, Head of Incyte Intl
Sale1,471$121.89$179,300.19View Details
Nov 13, 2026
Heeson Lee
EVP, Head of Incyte Intl
Sale3,700$120.33$445,223.59View Details
Nov 13, 2026
Heeson Lee
EVP, Head of Incyte Intl
Sale2,200$120.44$264,958.98View Details
Nov 6, 2026
Stein Steven H
CMO&Head of Late-Stage Dev.
Sale22,336$117.14$2,616,550.72View Details
Nov 6, 2026
Stein Steven H
CMO&Head of Late-Stage Dev.
Sale48,576$119.66$5,812,793.61View Details
Nov 6, 2026
Stein Steven H
CMO&Head of Late-Stage Dev.
Sale60,270$118.27$7,128,307.68View Details
Nov 6, 2026
Stein Steven H
CMO&Head of Late-Stage Dev.
Sale35,042$116.06$4,067,086.65View Details
Nov 6, 2026
Stein Steven H
CMO&Head of Late-Stage Dev.
Sale73,969$119.12$8,811,009.75View Details
Nov 3, 2026
Tray Thomas
Principal Accounting Officer
Sale610$118.96$72,565.60View Details
Oct 15, 2026
CAGNONI PABLO J
President, Global Head of R&D
Sale2,642$112.71$297,779.82View Details
Sep 15, 2026
CAGNONI PABLO J
President, Global Head of R&D
Sale13,985$120.49$1,685,052.65View Details
Sep 15, 2026
CAGNONI PABLO J
President, Global Head of R&D
Sale9,233$120.50$1,112,576.50View Details
Aug 19, 2026
CAGNONI PABLO J
President, Global Head of R&D
Sale10,801$125.56$1,356,173.56View Details
38 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Oct 29, 2026
EPS
Estimated-$3.20
ActualN/A
Revenue
Estimated$1.47B
ActualN/A
Oct 27, 2026
EPS
Estimated-$3.20
ActualN/A
Revenue
Estimated$1.47B
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1